NCT03721588 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Agosti V, Chen Y, Levin FR
Does Attention Deficit Hyperactivity Disorder increase the risk of suicide attempts? J Affect Disord. 2011 Oct;133(3):595-9. doi: 10.1016/j.jad.2011.05.008. Epub 2011 Jun 11.
Duran S, Fistikci N, Keyvan A, Bilici M, Çaliskan M
[ADHD in adult psychiatric outpatients: prevalence and comorbidity]. Turk Psikiyatri Derg. 2014 Summer;25(2):84-93. Turkish.
Ekinci S, Öncü B, Canat S
Adult attention deficit hyperactivity disorder: comorbidity and functioning. Anadolu Psikiyatr Derg 2011;12:185-1.
Tamam L, Demirkol ME
Adult attention deficit/hyperactivity disorder and mood disorders. Turkiye Klin J Psychiatry-Special Top 2012;5:48-3.

Evaluation of Clinical and Suicidal Behavior Characteristics Among Urban, Turkish Middle-Age Depressive Patients With Comorbid Adult Attention Deficit Hyperactivity Disorder

Details for clinical trial NCT03721588

Clinical trial NCT03721588 - References